Sanofi Taps Nestle's Roger as CFO After Swing to Net Loss
By Adria Calatayud
Sanofi named Nestle's Francois-Xavier Roger as its new chief financial officer and reported a swing to a net loss for the fourth quarter despite strong sales of its blockbuster drug Dupixent.
The French pharmaceutical company said Thursday that Roger, who has been CFO at Nestle for more than eight years, will replace Jean-Baptiste Chasseloup de Chatillon, who is stepping down. The change will be effective from April 1.
Net loss for the fourth quarter was 555 million euros ($600.5 million) compared with a profit of EUR3.11 billion for the same period of 2022, Sanofi said. Higher costs and exceptional items hit the company's profitability.
Business operating profit--one of the company's preferred metrics, which strips out exceptional items--fell 5.2% to EUR2.58 billion.
Net sales rose 1.8% to EUR10.92 billion. At constant currency, sales were up 9.3%, with growth in its specialty-care unit driven by continued strength in anti-inflammatory drug Dupixent--jointly developed with Regeneron Pharmaceuticals--and in vaccines.
Analysts expected business operating profit of EUR2.77 billion on sales of EUR11.04 billion, according to estimates provided by the company.
Sanofi reiterated its outlook for 2024.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
February 01, 2024 02:01 ET (07:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 2024 Stock Market Outlook: Is the AI Stock Trade Over?
-
Ian Bremmer: 4 Big Geopolitical Risks to Watch
-
What’s Happening In the Markets This Week
-
Obesity Drug Stocks: Why It Will Be ‘Exceptionally Difficult’ to Dethrone Eli Lilly and Novo Nordisk
-
What Does Chipotle’s Stock Split Mean for Investors?
-
5 Stocks to Buy Before the Fed Cuts Interest Rates in 2024
-
Markets Brief: Inflation Is Back In the Spotlight
-
What a Strong Economy Now Means for the Rest of 2024
-
10 Top Dividend Stocks for 2024
-
Finding Small-Cap Stock Opportunities In a Big-Cap World
-
The 10 Best Companies to Invest in Now
-
Nike Earnings: Dim Sales Outlook Slams Shares, but Patient Investors Could Be Rewarded
-
2 Top E-Commerce Stock Picks
-
Our Top Pick for Investing in US Renewable Energy
-
Micron Earnings: We Raise Our DRAM Forecast and Valuation Behind Stronger Pricing Assumptions
-
10 Undervalued Wide-Moat Stocks